MA41842A - Nouveaux procédés de sélection d'épitope - Google Patents

Nouveaux procédés de sélection d'épitope

Info

Publication number
MA41842A
MA41842A MA041842A MA41842A MA41842A MA 41842 A MA41842 A MA 41842A MA 041842 A MA041842 A MA 041842A MA 41842 A MA41842 A MA 41842A MA 41842 A MA41842 A MA 41842A
Authority
MA
Morocco
Prior art keywords
epitopic
new
selection processes
selection
processes
Prior art date
Application number
MA041842A
Other languages
English (en)
Inventor
Owe Orwar
Carolina Trkulja
Original Assignee
Oblique Therapeutics Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oblique Therapeutics Ab filed Critical Oblique Therapeutics Ab
Publication of MA41842A publication Critical patent/MA41842A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21004Trypsin (3.4.21.4)
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00Methods of screening libraries
    • C40B30/04Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA041842A 2015-03-31 2016-03-30 Nouveaux procédés de sélection d'épitope MA41842A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562140955P 2015-03-31 2015-03-31
US201562283118P 2015-08-21 2015-08-21

Publications (1)

Publication Number Publication Date
MA41842A true MA41842A (fr) 2018-02-06

Family

ID=55701934

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041842A MA41842A (fr) 2015-03-31 2016-03-30 Nouveaux procédés de sélection d'épitope

Country Status (15)

Country Link
US (2) US11161901B2 (fr)
EP (1) EP3277724A1 (fr)
JP (1) JP6967507B2 (fr)
KR (1) KR102714297B1 (fr)
CN (1) CN107531792A (fr)
AU (2) AU2016240208B2 (fr)
HK (1) HK1249124A1 (fr)
IL (1) IL254795B2 (fr)
MA (1) MA41842A (fr)
MX (1) MX391005B (fr)
NZ (1) NZ735823A (fr)
RU (2) RU2022100590A (fr)
SG (1) SG11201707945TA (fr)
WO (1) WO2016156545A1 (fr)
ZA (1) ZA201707369B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3392654A4 (fr) 2015-12-14 2019-08-21 Morinaga Institute of Biological Science Inc. Procédé de détection de protéines, et procédé de dosage immunologique de protéines
US11136362B2 (en) * 2016-03-10 2021-10-05 The Board Of Trustees Of The Leland Stanford Junior University Peptide modulators of specific calcineurin protein-protein interactions
GB201614884D0 (en) * 2016-09-01 2016-10-19 Oblique Therapeutics Ab Method
GB201617002D0 (en) * 2016-10-06 2016-11-23 Oblique Therapeutics Ab Multi-protease method
CN107991495B (zh) * 2017-11-27 2020-08-07 河南科技大学 一种提高膜蛋白序列检测覆盖率的质谱样品的制备方法
JP6712369B2 (ja) * 2018-05-29 2020-06-24 株式会社森永生科学研究所 抗ペプチド抗体の製造方法及び設計方法
GB201918103D0 (en) * 2019-12-10 2020-01-22 Oblique Therapeutics Ab Epitopes and antibodies
GB202019522D0 (en) * 2020-12-10 2021-01-27 Oblique Therapeutics Ab Epitopes and antibodies

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07500486A (ja) * 1990-10-18 1995-01-19 カンサーフォースクニングスフォンデン・アフ・1989(フォンデン・チル・フレメ・アフ・エクスペリメンテル・カンサーフォースクニング) ウロキナーゼレセプターに対する抗体とその用途
CN100387718C (zh) * 1995-03-17 2008-05-14 益得生物医学公司 抗蛋白酶k降解的脑膜炎奈瑟氏球菌表面蛋白
IL117483A (en) * 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
IL138946A0 (en) 2000-10-11 2001-11-25 Compugen Ltd Method for the identification of peptides and proteins
KR20040018459A (ko) * 2001-07-13 2004-03-03 메르크 파텐트 게엠베하 폴리펩티드 면역원성의 감소방법
CN100558879C (zh) * 2002-10-03 2009-11-11 诺曼·利·安德森 用质谱法高灵敏度定量肽
US7632686B2 (en) 2002-10-03 2009-12-15 Anderson Forschung Group High sensitivity quantitation of peptides by mass spectrometry
CN1849138B (zh) 2003-07-15 2011-11-30 安姆根有限公司 作为选择性ngf途径抑制剂的人抗ngf中和抗体
WO2005074923A1 (fr) * 2004-02-03 2005-08-18 Agt Biosciences Limited Methodes et compositions
WO2006005472A1 (fr) 2004-07-15 2006-01-19 Bayer Healthcare Ag Diagnostics et therapies de maladies associees au recepteur vanilloide (vr1)
US20060292639A1 (en) * 2004-08-13 2006-12-28 Adolor Corporation Splice variant of the vanilloid receptor VR1A
WO2006047417A2 (fr) 2004-10-21 2006-05-04 University Of Florida Research Foundation, Inc. Detection de biomarqueurs du recepteur cannabinoide et utilisations
SE0403139D0 (sv) 2004-12-23 2004-12-23 Nanoxis Ab Device and use thereof
JP2008175814A (ja) 2006-12-21 2008-07-31 Eisai R & D Management Co Ltd 尿中タンパク質分子の検出・定量による糖尿病性腎症の検査方法及びそれに使用するキット
US20120052592A9 (en) 2007-03-30 2012-03-01 Nano Solution, Inc., Method for determining prognosis of acute central nervous system disorder
KR101649168B1 (ko) 2008-05-09 2016-08-18 애브비 인코포레이티드 최종 당화 산물의 수용체(rage)에 대한 항체 및 이의 용도
WO2010096385A2 (fr) 2009-02-17 2010-08-26 The Regents Of The University Of Colorado, A Body Corporate, A Colorado Non-Profit Procédés et compositions pour le traitement des maladies auto-immunes
US9234037B2 (en) 2009-10-27 2016-01-12 Ucb Biopharma Sprl Method to generate antibodies to ion channels
US9383367B1 (en) 2010-12-07 2016-07-05 Chunli Liu Methods of detecting conjugation site-specific and hidden epitope/antigen
WO2013020557A1 (fr) 2011-08-08 2013-02-14 Syddansk Universitet Procédé et anticorps pour l'identification de protéines ubiquitinées et de sites d'ubiquitination
CA2902026C (fr) 2013-03-13 2023-08-29 Prothena Biosciences Limited Immunotherapie contre tau
GB201617002D0 (en) 2016-10-06 2016-11-23 Oblique Therapeutics Ab Multi-protease method

Also Published As

Publication number Publication date
IL254795A0 (en) 2017-12-31
SG11201707945TA (en) 2017-10-30
CN107531792A (zh) 2018-01-02
RU2764992C2 (ru) 2022-01-24
ZA201707369B (en) 2019-02-27
AU2022202251B2 (en) 2024-08-22
US20220073607A1 (en) 2022-03-10
KR102714297B1 (ko) 2024-10-07
US11912765B2 (en) 2024-02-27
IL254795B2 (en) 2023-09-01
AU2016240208A1 (en) 2017-10-19
AU2022202251A1 (en) 2022-04-21
HK1249124A1 (zh) 2018-10-26
AU2016240208B2 (en) 2022-01-27
EP3277724A1 (fr) 2018-02-07
RU2017134875A (ru) 2019-05-06
JP6967507B2 (ja) 2021-11-17
MX2017012284A (es) 2018-06-20
IL254795B1 (en) 2023-05-01
CA2981108A1 (fr) 2016-10-06
US11161901B2 (en) 2021-11-02
US20180111990A1 (en) 2018-04-26
RU2017134875A3 (fr) 2019-09-13
BR112017021026A2 (pt) 2018-11-06
WO2016156545A1 (fr) 2016-10-06
KR20170136551A (ko) 2017-12-11
RU2022100590A (ru) 2022-03-10
NZ735823A (en) 2023-07-28
MX391005B (es) 2025-03-21
JP2018509942A (ja) 2018-04-12

Similar Documents

Publication Publication Date Title
EP3765021A4 (fr) Nouveaux procédés
MA55748A (fr) Procédés de détection d'aav
EP3464313A4 (fr) Nucléotides modifiés 5 '-cyclo-phosphonate
EP3430731A4 (fr) Architecture d'iugw
EP3308907A4 (fr) Machine d'entraînement
EP3492223A4 (fr) Machine d'entraînement
EP3302575A4 (fr) Vecteurs d'édition de génome
EP3360118A4 (fr) Alarme d'écoulement
HUE052294T2 (hu) Vitorlahajtású hajó
MA41842A (fr) Nouveaux procédés de sélection d'épitope
EP3558312A4 (fr) Procédés d'amélioration de la densité vasculaire
EP3443293A4 (fr) Capteurs d'effort
EP3433383A4 (fr) Procédés d'amplification quantitative
MA41298A (fr) Procédés de marquage de banques codées par de l'adn
EP3563912A4 (fr) Machine à ramer
EP3359994A4 (fr) Système d'autopropulsion
EP3343013A4 (fr) Collecteur d'admission
EP3341151A4 (fr) Machine d'oxycoupage au chalumeau
FR3034130B1 (fr) Demontage d'aubes de soufflante
FR3038247B1 (fr) Machine d'etirage de film
EP3380840A4 (fr) Procédés de prédiction de la progression de l'endobrachyoesophage
EP3305767A4 (fr) Nouveaux antagonistes de tlr2
ES1109830Y (es) " senalador de prendas"
MA46088A (fr) Procédés d'identification d'épitopes
EP3265469A4 (fr) Nouveaux procédés de synthèse